Lily Issued Third Complete Response Letter in 2023, Second Time on Issues Related to Manufacturing

October 2, 2023 |

Eli Lilly announced on Monday that it has received its second FDA complete response letter (CRL) related to findings from an inspection of the third-party contract manufacturing organization, this time for production of the company’s eczema drug, Lebrikizumab.
Source: Drug Industry Daily